Caitlin Costello, MD

home / authors / caitlin-costello-md

Articles

Choosing Between Triplet and Quadruplet Induction Regimens for Transplant-Eligible NDMM

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

March 25th 2022

A discussion on choosing between triplet or quadruplet induction therapy for transplant-eligible newly diagnosed multiple myeloma.

Triplet and Quadruplet Induction Regimens for Transplant-Eligible NDMM: Focus on GRIFFIN and MASTER Trials

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

March 25th 2022

An overview of the triplet and quadruplet induction treatment regimens available for patients with transplant-eligible multiple myeloma and key clinical trials studying daratumumab and isatuximab presented at ASH 2021, with emphasis on the GRIFFIN, MASTER and GMMG-HD7 studies.

Transplant-Ineligible MM: Navigating Treatment Challenges

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

October 15th 2021

A panel of hematologists/oncologists conclude a discussion about transplant-ineligible multiple myeloma (MM) by reacting to current treatment gaps that need to be addressed.

Counseling Patients With MM About Treatment Duration

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

October 13th 2021

Recommendations when talking with patients with transplant-ineligible multiple myeloma (MM) who request to stop receiving treatment.

Transplant-Ineligible MM: Reinitiating Therapy

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

October 8th 2021

Triggers that may lead a hematologist/oncologist to consider reinstituting therapy for a patient with transplant-ineligible multiple myeloma (MM) who received prior therapy but was not treated to progression.

Transplant-Ineligible MM: Treating to Progression

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

October 6th 2021

The rationale behind treating patients with newly diagnosed transplant-ineligible multiple myeloma (MM) until disease progression rather than stopping therapy at a designated point in time.

Maintenance Therapy for Transplant-Ineligible MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

October 1st 2021

Take-home points from the MAIA trial of daratumumab plus lenalidomide and dexamethasone as therapy for patients with newly diagnosed transplant-ineligible multiple myeloma, and recommendations regarding maintenance therapy following the use of a triplet regimen.

Triplet Vs Doublet Therapy for Transplant-Ineligible MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 29th 2021

Scenarios for which a doublet regimen may be recommended over a triplet therapy for the management of newly diagnosed transplant-ineligible multiple myeloma.

Managing A Case of Newly-Diagnosed Transplant-Ineligible MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 24th 2021

A panel of hematologist-oncologists comment on how they would treat a 74-year-old patient with newly diagnosed transplant-ineligible multiple myeloma.

Managing Adequate/Inadequate Treatment Response in MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 22nd 2021

Recommended next steps regarding treatment for patients with transplant-ineligible multiple myeloma based on prior responses to therapy.

MRD Testing in Multiple Myeloma

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 17th 2021

Current techniques used to assess MRD status in patients with multiple myeloma, and advice to hematologist-oncologists who are considering flow cytometry or molecular testing.

Frequency of Measuring Treatment Response in MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 15th 2021

Recommendations for measuring treatment response in patients with multiple myeloma utilizing tests such as MRD assessments.

Strategies to Monitor Multiple Myeloma

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 10th 2021

Different markers and tests that are used to monitor disease status and treatment response in patients with multiple myeloma.

Goals of Therapy for Transplant-Ineligible MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 8th 2021

Kicking off a discussion regarding treatment approaches for transplant-ineligible multiple myeloma, a panel of hematologist-oncologists highlights goals of therapy for newly diagnosed patients.

A 60-Year-Old Man With Progressive Anemia While Receiving Checkpoint Blockade Therapy for Relapsed Myelofibrosis

Aaron M. Goodman, MD;Megan Rust, MD;Caitlin Costello, MD;Edward D. Ball, MD

February 15th 2017

A 60-year-old man with a history of coronary artery disease and JAK2 V617F–positive polycythemia vera presented to our bone marrow transplantation clinic with progressive fatigue, splenomegaly, and cytopenias.

<1 2 3